Duane Gubler | Emeritus Professor, Programme In Emerging Infectious Diseases
Duke-NUS Graduate Medical School

Duane Gubler, Emeritus Professor, Programme In Emerging Infectious Diseases, Duke-NUS Graduate Medical School

Dr Duane J Gubler, ScD, FAAAS, FIDSA, FASTMH, is Emeritus Professor and founding director, Signature Research Program in Emerging Infectious Diseases at the Duke-NUS Medical School, Singapore. He is Adjunct Professor in his alma mater, Johns Hopkins Bloomberg School of Public Health, the Duke University School of Medicine and Duke Global Health Institute. He has spent his entire career working on tropical infectious diseases with an emphasis on dengue and other Aedes-transmitted diseases. He has extensive field experience in Asia, the Pacific, tropical America and Africa, and has published extensively on all aspects of dengue and other vector-borne infectious diseases, with over 350 publications and 2 books to his credit. Prof Gubler was founding Chief of the Dengue Branch, United States Centers for Disease Control and Prevention (CDC) in Puerto Rico for 9 years, Director of the Division of Vector-Borne Infectious Diseases, CDC in Fort Collins, Colorado for 15 years and Chair, Department of Tropical Medicine, Medical Microbiology and Pharmacology, University of Hawaii School of Medicine, in Honolulu for 5 years. He has and continues to serve on numerous WHO, national and international committees and study groups, and on the Scientific Advisory Boards of a number of companies and institutions. Prof Gubler was founding Chair, Board of Councillors, Pediatric Dengue Vaccine Initiative in Seoul, Korea, founding Chair, Partnership for Dengue Control in Lyon, France, and the Global Dengue and Aedes-transmitted Diseases Consortium in Seoul, Korea, for which he currently serves as Chairman. Prof Gubler is a Fellow, Infectious Disease Society of America, Fellow, American Association for the Advancement of Science, and Fellow and Past President of the American Society of Tropical Medicine and Hygiene.

Appearances:



April 16 Day 2 - 10 Co-conferences @ 15:10

Dengue on trial

  • Update on efficacy studies of the live attenuated dengue vaccine TV003/005
  • Progress of the Butantan dengue Phase III clinical trial
  • The dengue vaccine program at Merck
  • WHO recommendations for Dengvaxia

April 16 Day 2 - 10 Co-conferences @ 16:40

The global vector control response: The issue of integrating vaccine with vector control with a focus on new VC technology

  • Where are we on dengue, malaria, chikungunya, yellow fever and Zika
  • How can vaccines and vector control be integrated and used synergistically and has it worked?
last published: 21/Mar/19 15:25 GMT

back to speakers

Sign Up for Event Updates

Get Involved At World Vaccine Congress Washington

 

To Sponsor Or Exhibit

Marc Rhys-Evans
marc.rhys-evans@terrapinn.com
+44 20 7827 5945

 

 

 

To Register

Tayyab Abbasi
tayyab.abbasi@terrapinn.com
+44 20 7092 1210

 

 

 

Press Relations

Karina Kusova
karina.kusova@terrapinn.com
+44 20 7092 1071